Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy

Obstetrics and Gynecology

Volumn 93, Issue 4 SUPPL., 1999, Pages 551-557

  Van De Weijer, Peter H M ^a   Barentsen, Ronald ^b   De Vries, Michiel ^b   Kenemans, Peter ^b  

^a Hospital Centre Apeldoorn   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DYDROGESTERONE; ESTRADIOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLEEDING DISORDER; BREAKTHROUGH BLEEDING; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; FEMALE; HEADACHE; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; VAGINA BLEEDING; WEIGHT REDUCTION;

ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYDROGESTERONE; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PROGESTERONE CONGENERS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SMOKING; UTERINE HEMORRHAGE;

EID: 0033045752     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006250-199904000-00016     Document Type: Article

References (26)

1. te Velde ER, Leusden van HAIM. Hormonal treatment for the climacteric: Alleviation of symptoms and prevention of postmenopausal disease. Lancet 1994;343:654-8.
2. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger VL, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
3. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1945;85:304-13.
4. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-23.
5. Mattson LA, Cullberg G, Samaioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 1982:4;95-102.
6. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: A critical review Obstet Gynecol 1995;86:306-16.
7. Ferenczy A, Gelfand MM. Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas 1997;26:219-26.
8. Burch DJ, Spowart KJM, Jesinger DK, Randall S, Smith SK. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17 β oestradiol. Br J Obstet Gynaecol 1995;102:243-8.
9. Stumpf PG. Pharmacokinetics of estrogen. Obstet Gynecol 1990;75: 9S-14S.
10. Thomas CMG, Van den Berg RJ, Segers MFG, Bartelink ML, Thien T.Inaccurate measurements of 17β-oestradiol in serum of female volunteers after oral administration of milligram amounts of micronised 17β-oestradiol. Clin Chem 1993;39:2341-2.
11. Belsey EM, Farley TMM. The analysis of menstrual bleeding patterns: A review. Contraception 1988;38:129-56.
12. Clisham PR, de Ziegler D, Lozano K, Judd HJ. Comparison of continuous versus sequential estrogen and progestin therapy in postmenopausal women. Obstet Gynecol 1991;77:241-6.
13. Magos AL, Brincat M, Studd JWW, Wardle P, Schlesinger P, O'Dowd O, Amenorrhoea and endometrial atrophy with continuous oral estrogens and progestogen therapy in postmenopausal women. Obstet Gynecol 1985;65:496-9.
14. Dören M, Schneider HPG. Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women. Maturitas 1996;25:99-105.
15. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol 1990;162:502-14.
16. Cassidenti DL, Vijod AG, Vijod MA, Stanczyk FZ, Lobo RA. Short-term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women. Am J Obstet Gynecol 1990;163:1953-60.
17. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HE, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med 1986;315:1305-9.
18. Archer DF, Pickar JH, Bottiglioni F, for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686-92.
19. Sporrong T, Hellgren M, Samsioe G, Mattson LA. Comparison of four continously administered progestogen plus estradiol combinations for climacteric complaints. Br J Obstet Gynaecol 1988;95: 1042-8.
20. Hillard TC, Siddle NC, Whitehead MI, Fraser DI, Pryse-Davies J. Continuous combined conjugated equine estrogen-progestogen therapy: Effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol 1992;167:1-7.
21. Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol 1987;69:929-32.
22. Hickey M, Lau TM, Russell P, Fraser LS, Rogers PAW.Micro vascular density in conditions of endometrial atrophy. Hum Reprod 1996;11:2009-13.
23. Tabibazadeh S. The signals and molecular pathways involved in human menstruation, a unique process of tissue destruction and remodeling. Mol Hum Reprod 1996;2:77-92.
24. Ferenczy A, Gelfand MM. Endometrial histology and bleeding patterns in postmenopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas 1997;26:219-26.
25. Gelfand MM, Fugere P, Bissonnette F, Wiita B, Yang HM, Lorrain J, et al. Conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone acetale in postmenopausal women: Effects on lipoproteins, glucose tolerance, endometrial histology and bleeding. Menopause 1997;4:10-18.
26. van de Weijer PHM, Mol M, Biesheuvel E. Vaginal bleeding patterns during sequential regimens of oestradiol and dydrogesterone. Eur Menopause J 1995;4:9-16.